Safety and Feasibility of Human Umbilical Cord Mesenchymal Stem Cell-Derived Secretome in the Treatment of Liver Cirrhosis: a Comprehensive Evaluation of Fibrosis Reduction, Immunomodulation, and Hepatic Regeneration: a Single Center, Randomized, Phase I Clinical Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-01

Study Completion Date

2026-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if Human Umbilical Cord Mesenchymal Stem Cell (HUCMSC) derived secretome injection is safe and effective in patient with liver cirrhosis. The main questions it ams to answer are:

1. How safe is secretome Injection as an adjuvant therapy for liver cirrhosis patients?
2. How effective is secretome injection in liver fibrosis 6 months after injection?
3. Does secretome injection improve liver function after 6 months after Injection?
4. Does secretome injection affect Child Turcotte Pugh score?
5. How does secretome affect pro inflammatory and anti Inflammatory cytokine in patient with liver cirrhosis?
6. How does secretome injection affect the quality of life in live cirrhosis patient?
7. What is the relationship between secretome injection and encephalopathy? Researchers will compare secretome injection group (patients who recieve secretome injections) to best practice treatment group (patient who receive supportive treatment including hepatoprotector and ursodeoxycolic acid)

Researchers will compare the intervention group (patients who are injected with HUCMSC derived secretome) and control group (patients who are only monitored and given their usual drugs)

Patients will:

Be injected with secretome or take hepatoprotector and ursodeoxycolic acid every 2 weeks for 4 months. Do several test such us fibroscan, stroop test, psychometric hepatic encephalopathy score, short form 36 questionnaire, IL-6, TNF alfa and blood test for albumin, SGOT, SGPT, direct bilirubin, indirect bilirubin, INR, creatinine, ureum, hemoglobin, hematocrite, leukocyte, and thrombocyte.

Visit the clinic once every two weeks to receive drugs and treatment for 4 months.

Follow up visit to review treatment progress on 3rd months (2 weeks post treatment), 7th months (3 months post treatment),10th months (6 months post treatment)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis

NCT03529136

Decompensated Liver Cirrhosis

UNKNOWN PHASE2

Umbilical Cord-derived Mesenchymal Stem Cell Infusion for Treating ACLF

NCT06884904

Acute-On-Chronic Liver Failure

NOT_YET_RECRUITING PHASE2/PHASE3

Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis

NCT02652351

Hepatic Cirrhosis

UNKNOWN PHASE1

Mesenchymal Stem Cell Therapy for Liver Cirrhosis

NCT03626090

Liver Cirrhosis

UNKNOWN PHASE1/PHASE2

Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)

NCT05224960

Decompensated Cirrhosis

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cirrhosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Secretome Injection

patient will receive secretome injection every two weeks for four months

Group Type EXPERIMENTAL

Secretome

Intervention Type DRUG

3 ml Injection of secretome for 8 times two weeks apart

Best Treatment Practice

patient will receive hepatoprotector drugs and Urodeoxycolate acid for four months

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Secretome

3 ml Injection of secretome for 8 times two weeks apart

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

hepatoprotector drugs ursodeoxycholic acid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age above 17 years, both men and women
* Patient is willing to participate and sign informed consent
* Patient is diagnosed with liver cirrhosis confirmed by clinical examination and diagnostic imaging
* Liver cirrhosis patient with Child-Pugh Class B
* Patient is in a stable condition without life threatening complications such as active gastrointestinal bleeding, severe infection, severe renal failure (eGFR\&amp\>30) at time of registration
* Patient is not receiving experimental drugs for liver cirrhosis for the past 6 months
* Patient is able and willing to comply with research protocol including follow up visits and evaluations

Exclusion Criteria

* Patient with uncontrolled psychiatric disorders
* Patient who is diagnosed with hepatic or non- hepatic malignancy
* Lactating and pregnant patient
* Patient who has allergy or hypersensitivity reaction towards secretome

Minimum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No